Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Director/PDMR Shareholding

21st Sep 2018 10:15

RNS Number : 5462B
Cello Health PLC
21 September 2018
 

21 September 2018

 

Cello Health plc

("Cello" or the "Group")

 

Director/PDMR Shareholding

 

The Group provides the following notification in accordance with Article 19(3) of the Market Abuse Regulation:

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Alasdair Combe

2

Reason for the notification

a)

Position/status

Person closely associated with Jane Shirley, Joint CEO of Cello Health Insight and CEO of Cello Health Europe

b)

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Cello Health plc

b)

LEI

2138004TZYGZLWQP7N64

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Ordinary shares of 10 pence each

Identification code

ISIN: GB00B0310763

b)

Nature of the transaction

Purchase of ordinary shares

c)

 

Price(s) and volume(s)

Price(s)

Volume(s)

£1.3487

10,000

d)

 

Aggregated information

- Aggregated volume

10,000

- Price

£13,487.00

e)

Date of the transaction

20 September 2018

f)

Place of the transaction

AIMX

 

 

Enquiries:

 

Cello Health plc

020 7812 8460

Mark Scott, Chief Executive

Mark Bentley, Finance Director

Cenkos Securities plc

0207 397 8900

Mark Connelly

Harry Hargreaves

 

Notes to Editors

Cello Health plc is a global healthcare-focused advisory Group comprised of a set of leading clinical, commercial advisory and digital delivery capabilities. Cello Health plc currently services 24 of the top 25 pharmaceutical clients globally, as well as a wide range of biotech, diagnostics, devices and other key non-healthcare clients.

Cello Health plc enables clients to commercialise, differentiate their assets, and drive brand success in ever more complex global markets. The business delivers its services through nearly 1,000 highly skilled professionals, utilising latest thinking, technology and digital solutions.

Cello Health plc delivers its services from an office network in the UK, USA, and Asia, with hub offices in New York City, Philadelphia PA, London, Edinburgh, Farnham and Cheltenham.

For further information, please visit: https://cellohealthplc.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHFKDDKCBKKFCB

Related Shares:

CLL.L
FTSE 100 Latest
Value8,809.74
Change53.53